文章来源：免疫炎症事业部中央市场部

摘要信息：2025年新增科室会幻灯、希为纳VS乌司他丁

文章来源：免疫炎症事业部中央市场部

摘要信息：心外围术期的肺保护策略

文章来源：中国知网

摘要信息：目的 探析西维来司他钠联合俯卧位通气在急性肺损伤（ALI）/急性呼吸窘迫综合征（ARDS）中的疗效。方法 确认研究样本为50例ALI/ARDS患者，来源潍坊市第二人民医院，研究起止时间2023年10月至2024年9月，以随机数字法设计分组，分成对照组（25例，常规治疗）和试验组（25例，在对照组的基础上增加静脉泵入西维来司他钠联合俯卧位通气治疗）。评价组间血气指标[动脉血氧饱和度（SaO2）、动脉血氧分压（PaO2）、动脉血二氧化碳分压（PaCO2）]、临床指标、病死率及并发症发生情况。结果 试验组血气指标高于对照组（P<0.05）；试验组症状缓解时间及住院时间均短于对照组（P<0.05）；试验组并发症总发生率低于对照组（P<0.05）。结论 西维来司他钠与俯卧位通气联合使用，有助于改善ALI/ARDS患者的血气水平，加速症状缓解，缩短住院时间，并降低并发症的发生率。

文章来源：PubMed

摘要信息：Background. Since the 2012 Berlin Definition of the Acute Respiratory Distress Syndrome (ARDS), several developments have supported the need for an expansion of the definition, including the use of high flow nasal oxygen (HFNO), expanding use of pulse oximetry in place of arterial blood gases, use of ultrasound for chest imaging, and the need for applicability in resource-limited settings. Methods. A Consensus Conference of 32 critical care ARDS experts was convened, had six virtual meetings (June 2021-March 2022), and subsequently obtained input from members of several critical care societies. The goal was to develop a definition that would: (1) identify patients with the currently accepted conceptual framework for ARDS; (2) facilitate rapid ARDS diagnosis for clinical care and research; (3) be applicable in resource-limited settings; (4) be useful for testing specific therapies; and (5) be practical for communication to patients and caregivers. Results. The committee made four main recommendations: (1) Include HFNO with a minimum flow rate of  30 liters/min; (2) Use arterial oxygen tension (PaO2)/FiO2  300 mmHg or SpO2/FiO2 < 315 (if SpO2  97%) to identify hypoxemia; (3) Retain bilateral opacities for imaging criteria but add ultrasound as an imaging modality, especially in resource-limited areas; and (4) In resource-limited settings, do not require PEEP, oxygen flow rate, or specific respiratory support devices. Conclusions. We propose a New Global Definition of ARDS that builds on the Berlin Definition. The recommendations also identify areas for future research, including the need for prospective assessments of feasibility, reliability, and prognostic validity of the proposed Global Definition.

文章来源：PubMed

摘要信息：Objective:Sivelestat may reduce postoperative pulmonary injury after total arch replacement (TAR). This study aimed to evaluate whether the preoperative PaO2/FiO2(P/F) ratio affects the efficacy of sivelestat in reducing postoperative pulmonary injury in patients with acute aortic dissection (AAD) who underwent TAR using deep hypothermic circulatory arrest (DHCA). Methods:Data of patients with AAD who underwent TAR using DHCA in a tertiary hospital between February 1, 2022, and December 30, 2022, were retrospectively reviewed. The patients were divided into the sivelestat and control groups. Three subgroup analyses were performed based on the postoperative P/F ratio. The primary clinical outcomes were assessed to determine the efficacy and safety of sivelestat in managing postoperative pulmonary dysfunction in patients undergoing cardiopulmonary bypass. Results:A total of 187 patients were included, with 95 in the sivelestat group and 92 in the control group. No significant differences were found in the clinical variables between the two groups (all P > 0.05), except for some improvements in the inflammatory biomarker levels (including white blood cell count, neutrophil count, and C-reactive protein). Subgroup analysis revealed that sivelestat treatment significantly increased the P/F ratio on the 4th day and 3rd day after TAR in patients with mild lung injury (P = 0.02) and moderate lung injury (P = 0.03), respectively. Additionally, sivelestat reduced the levels of several postoperative inflammatory biomarkers in both subgroups. Conclusions:Among patients with AAD with mild or moderate preoperative lung injury, defined by a low P/F ratio, sivelestat significantly improved the postoperative P/F ratio and attenuated inflammatory responses after TAR. These findings suggest an important avenue for further research.

文章来源：中国知网

摘要信息：目的 比较西维来司他钠与乌司他丁对急性Stanford A型主动脉夹层（ATAAD）手术患者术后切口感染的效果。方法 回顾性分析2022年1月至2023年1月行ATAAD患者109例，分为观察组（50例）和对照组（59例）。观察组患者接受西维来司他钠治疗，对照组患者接受乌司他丁治疗。主要结局指标为术后至出院前的切口感染发生率。次要结局指标为术后肺部并发症（PPCs）、术后气管导管拔管时间、重症监护室（ICU）入住时间及术后住院时间；麻醉诱导前10 min（T0）、切皮时（T1）、术毕即刻（T2）、术后24 h （T3）及术后72 h（T4）时测量患者肺泡-动脉血氧分压差(PA-aDO2)、肺泡氧合指数（OI）及呼吸指数（RI）。术前1 d、术后1 d及术后3 d时分别采集患者外周静脉血样本，测定白细胞计数（WBC）、中性粒细胞数量（NEUT）、中性粒细胞百分比（NEUT%）及C反应蛋白（CRP）水平。结果 对照组术后切口感染发生率为13.6%（8/59）,观察组为4.0%（2/50）,观察组低于对照组（P<0.05）。观察组患者术后气管导管拔管时间及ICU停留时间均较对照组缩短（P<0.05）。术后至出院前，与对照组比较，观察组高碳酸血症发生率降低（P<0.05）。观察组和对照组PPCs总发生率分别为10.0%和38.0%,前者较后者降低（P<0.05）。观察组T1～4时PA-aDO2和RI低于对照组、OI高于对照组（P<0.05）。观察组术后1 d和3 d时WBC、NEUT和NEUT%以及CRP水平均低于对照组，差异有统计学意义（P<0.05）。结论 与乌司他丁相比较，西维来司他钠可降低ATAAD患者术后切口感染发生率，抑制炎症反应。

文章来源：免疫炎症事业部中央市场部

摘要信息：希为纳®️分科室拜访场景卡：综合、呼吸、急诊、心外、神外、胸外、肝外分科室拜访场景卡。

文章来源：免疫炎症事业部中央市场部

文章来源：免疫炎症事业部中央市场部

文章来源：免疫炎症事业部中央市场部